Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Paul J Bröckelmann, Horst Müller, Sarah Gillessen, Anne Sophie Jacob, Jesko Momotow, Carla Damaschin, Justin Ferdinandus, Xiaoqin Yang, Michael Fuchs, Carsten Kobe, Hans Theodor Eich, Andreas Engert, Peter Borchmann, Bastian von Tresckow

Blood (2023) 142 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2023-188622

Published: 2023

Journal Articles

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Dennis A. Eichenauer, Ina Bühnen, Christian Baues, Carsten Kobe, Helen Kaul, Richard Greil, Alden Moccia, Joseé M. Zijlstra, Bernd Hertenstein, Max S. Topp, Marianne Just, Bastian von Tresckow, Hans-Theodor Eich, Michael Fuchs, Markus Dietlein, Sylvia Hartmann, Andreas Engert, Peter Borchmann

Blood (2023) 142 (6): 553–560.

https://doi.org/10.1182/blood.2023019939

Published: 2023

Journal Articles

Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors

Beate Klimm, MD, Helen Goergen, Michael Fuchs, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Hans Theodor Eich, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2012) 120 (21): 54.

https://doi.org/10.1182/blood.V120.21.54.54

Published: 2012

Journal Articles

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Blood (2012) 120 (21): 548.

https://doi.org/10.1182/blood.V120.21.548.548

Published: 2012

Journal Articles

Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

Andreas Engert, MD, Heinz Haverkamp, Carsten Kobe, MD, Jana Markova, MD, Christoph Renner, MD, Anthony D. Ho, MD, PhD, Josée Zijlstra, MD, Zdenek Král, MD, Harald Stein, MD, Hans Theodor Eich, MD, Rolf-Peter Müller, MD, Markus Dietlein, MD, Peter Borchmann, MD, Volker Diehl, MD

Blood (2011) 118 (21): 589.

https://doi.org/10.1182/blood.V118.21.589.589

Published: 2011

Journal Articles

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Andreas Engert, MD, Peter Borchmann, MD, Annette Pluetschow, Bastian von Tresckow, Jana Markova, Felicitas Hitz, Zdenek Kral, Richard Greil, MD, Max S Topp, Matthias Villalobos, Josee M. Zijlstra, Martin Soekler, Harald Stein, MD, Hans-Theodor Eich, Rolf-Peter Mueller, Michael Fuchs, Volker Diehl

Blood (2010) 116 (21): 765.

https://doi.org/10.1182/blood.V116.21.765.765

Published: 2010

Journal Articles

Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Peter Borchmann, Andreas Engert, Annette Pluetschow, Michael Fuchs, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max Topp, Matthias Villalobos, Jose Zijlstra, MD, Martin Soekler, Harald Stein, Hans Theodor Eich, Rolf Peter Mueller, Volker Diehl

Blood (2008) 112 (11): 367.

https://doi.org/10.1182/blood.V112.11.367.367

Published: 2008

Journal Articles

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

Volker Diehl, Heinz Haverkamp, Rolf Peter Mueller, Hans Theodor Eich, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Andreas Engert

Blood (2008) 112 (11): 1558.

https://doi.org/10.1182/blood.V112.11.1558.1558

Published: 2008

Journal Articles

HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany.

Andreas Engert, Jeremy Franklin, Rolf-Peter Mueller, Hans-Theodor Eich, Axel Gossmann, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony D. Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Beate Pfistner, Volker Diehl

Blood (2006) 108 (11): 99.

https://doi.org/10.1182/blood.V108.11.99.99

Published: 2006

Journal Articles

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Volker Diehl, Corinne Brillant, Andreas Engert, Ralf-Peter Mueller, Hans-Theodor Eich, Konrad Mueller-Hermelink, Richard Herrmann, Jana Markova, Anthony Ho, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Josting, Beate Pfistner

Blood (2005) 106 (11): 816.

https://doi.org/10.1182/blood.V106.11.816.816

Published: 2005

NARROW

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany.

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only